Effects of Chios mastic gum on cardiometabolic risk factors

doi:10.4239/wjd.v13.i11.921

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2552)

All Articles published online

The chart showing PDF series, WORD series, HTML series.

Item

Count

PDF

162

WORD

HTML

1779

Sum=1967

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

204

Download

381

Sum=585

Nov 15, 2022 (publication date) through May 23, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Diabetes. Nov 15, 2022; 13(11): 921-925
Published online Nov 15, 2022. doi: 10.4239/wjd.v13.i11.921

Effects of Chios mastic gum on cardiometabolic risk factors

Athanasia K Papazafiropoulou

Athanasia K Papazafiropoulou, The First Department of Internal Medicine and Diabetes Center, Tzaneio General Hospital of Piraeus, Piraeus 18536, Greece

Author contributions: Papazafiropoulou AK contributed to writing the manuscript.

Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Athanasia K Papazafiropoulou, MD, MSc, PhD, Attending Doctor, Research Scientist, The First Department of Internal Medicine and Diabetes Center, Tzaneio General Hospital of Piraeus, 1 Zanni and Afentouli Street, Piraeus 18536, Greece. pathan@ath.forthnet.gr

Received: July 24, 2022
Peer-review started: July 24, 2022
First decision: September 12, 2022
Revised: September 16, 2022
Accepted: October 11, 2022
Article in press: October 11, 2022
Published online: November 15, 2022

Core Tip

Core tip: Chios mastic gum (CMG), the resin produced by the trunk of Pistachia lentiscus var Chia, has been used for centuries as a strong phytotherapeutic therapy, primarily for the management of gastrointestinal diseases. Recently, there are studies demonstrating that it has hypolipidemic, cardioprotective and antidiabetic properties. Therefore, the aim of the present review is to summarize the existing literature data regarding the potential beneficial effects of CMG on cardiometabolic risk factors.